Nicox Ordinary and Extraordinary General Meetings of June 16, 2020
May 26, 2020
[vc_row][vc_column][vc_column_text]Dear Shareholder,
First of all I do hope that, in these critical times, you, your families and your loved ones are safe and healthy.
Today I am writing to you to request your continued support for Nicox by voting in our upcoming Ordinary and Extraordinary General Meetings convened on June 16, 2020.
Nicox made substantial progress in 2019 and in the first quarter of 2020. Most notably in the last quarter of 2019 we reported positive results of the Dolomites Phase 2 trial with our lead clinical product candidate NCX 470 in glaucoma patients and very encouraging results with NCX 4251 in the Danube Phase 2 trial in patients with blepharitis, which also showed potential for development in dry eye disease. In March this year, the significant amendment of the NCX 470 agreement with our Chinese partner Ocumension Therapeutics allowed us to considerably strengthen the Company’s financial position. Also in March, the End-of-Phase 2 meeting on NCX 470 with the U.S. Food and Drug Administration has given us a clear path forward to a future U.S. New Drug Application submission, and put us on track to initiate the first Phase 3 clinical trial expected by the end of Q2 2020. Last but not least, ZERVIATE was launched in the U.S. in March 2020 by our partner Eyevance Pharmaceuticals and discussions for other partnerships for this product are continuing worldwide.
As we look ahead to the remainder of 2020, we remain optimistic that, in spite of the overall situation due to the COVID-19 pandemic, we will be able to start the two Phase 3 trials with NCX 470 as announced and to plan for the next Phase 2b trial with NCX 4251. With these two product candidates in advanced phases of clinical development, and both targeting ocular indications with strong market potential, we believe we are well positioned to become a leading player in ophthalmology.
At the same time, we foresee a continued, progressive increase in our revenues in the future thanks to the growing global sales of VYZULTA by our partner Bausch + Lomb.
In order to continue to build on these achievements and advance our development programs, your support and your vote in the upcoming Ordinary and Extraordinary General Meetings are very important.
For this purpose, a proxy form, the resolutions, a guide explaining how to vote, and several other documents pertaining to the General Meetings are enclosed. You may either vote by proxy, by internet or attend the General Meetings in person on June 16, 2020 at 2:00 pm CET in the offices of BuroClub – Drakkar 2 – Bât D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France. All the documents pertaining to the General Meetings will be available on Nicox’s website www.nicox.com (‘Shareholder Meetings’ button on the home page) by May 26, 2020.
In the current public health context, the arrangements for physical participation in the shareholder meetings could be subject to modification. Shareholders are invited to regularly consult the section dedicated to the 2020 shareholder meetings on the Company’s website www.nicox.com. Shareholders can vote at shareholder meetings without being physically present, by voting by correspondence using the proxy form or by voting via Internet through the secure VOTACCESS platform as from May 29, 2020.
Should you have any question on the voting process, please contact our Investor Relations team either by e-mail at age2020nicox@nicox.com or by phone at +33 (0)4 97 24 53 25.
With my best regards,
Chairman & Chief Executive Officer[/vc_column_text][ultimate_spacer height=”20″][dt_default_button link=”url:https%3A%2F%2Fwww.nicox.com%2Fassets%2Ffiles%2FProxy-form-in-French.pdf||target:%20_blank|” size=”big” button_alignment=”btn_center” animation=”fadeIn” icon_type=”picker”]Get proxy form (in French)[/dt_default_button][/vc_column][/vc_row]